The Analytical Scientist / Issues / 2026 / January / GLP1 Analysis Riding the Wave of Peptide Innovation
Pharma and Biopharma Pharma and Biopharma Trends Liquid Chromatography

GLP-1 Analysis: Riding the Wave of Peptide Innovation

The remarkable commercial success of GLP-1 receptor agonists is fueling investment, accelerating science, and creating new analytical challenges. Here, we outline the hurdles these peptides present, explore methods for impurity profiling and structural characterization, and consider strategies to keep pace with this fast-moving field.

By Amanda M. Guiraldelli, Piotr Alvarez, Koen Sandra 01/26/2026 12 min read

Share

About the Author(s)

Amanda M. Guiraldelli

Senior Scientist at RIC group, Belgium

More Articles by Amanda M. Guiraldelli

Piotr Alvarez

Senior Scientist, RIC group, Belgium

More Articles by Piotr Alvarez

Koen Sandra

Koen Sandra is CEO, RIC, Kortrijk, Belgium.

More Articles by Koen Sandra

Recommended

Related Content

Loading the Molecular Dice
Pharma and Biopharma
Loading the Molecular Dice

December 12, 2024

2 min read

How a framework for controlling molecular reactions at the atomic scale has potential implications for nanotechnology, pharmaceutical synthesis, and clean energy research

CD-MS: To Megadalton and Beyond
Pharma and Biopharma
CD-MS: To Megadalton and Beyond

October 1, 2024

10 min read

Charge-detection mass spectrometry (CD-MS) has extended the range of MS to gigadalton-sized viruses and polymers; and with a commercial instrument in development and exciting new applications in complex protein mixtures, maturity beckons

New NMR Technique Enables Direct Detection of Molecular Chirality
Pharma and Biopharma
New NMR Technique Enables Direct Detection of Molecular Chirality

October 1, 2024

1 min read

Researchers develop an NMR method to distinguish between enantiomers without the need for chiral agents

Mass Spec Imaging Meets Proteomics
Pharma and Biopharma
Mass Spec Imaging Meets Proteomics

October 2, 2024

2 min read

Researchers combine tissue imaging with proteomics to shed light on the neurotoxic effects associated with HIV medication Efavirenz treatment